4CPS-089 Impact of the antimicrobial stewardship programme’s recommendations on the annual consumption of carbapenems
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance The complexity of infectious diseases and the increase in resistance make it necessary to establish antimicrobial stweardship programmes (ASP). Aim and Objectives To analyse the interventions carried out by the ASP on the consumption of carbapenems in a regional hospital. Material and Methods Observational study of the interventions carried out by the ASP on treatments with meropenem, ertapenem and imipenem throughout the year 2023. Variables analysed were: indication, empirical vs directed treatment, type of recommendation and acceptance or not of the intervention. The impact of the recommendations was correlated with antibiotic consumption, through the defined daily doses (DDD)/100 bed-days and their comparison with those of the previous year. Results During the study period, 129 interventions were carried out on carbapenem treatments, of which 45.7% were on meropenem, 53.5% on ertapenem and 0.8% on imipenem.The main indications for meropenem were respiratory infection (30.5%) and bacteraemia (25.4%). It was targeted therapy in 25% of the cases. The recommendations made were to maintain treatment (40.7%), de-escalate (27.1%), adjust duration (27.1%) and suspend (5.1%). They were fulfilled in 90% of the cases. Annual consumption during 2023 was 884.17 DDD/100 bed-days, achieving a decrease of 16% compared to the previous year (1052.36).The main indications for ertapenem were urinary infection (55.7%) and respiratory infection (17.4%). 59.4% of the cases were targeted therapy. Recommendations were to maintain treatment (31.9%), de-escalate (31.9%), adjust duration (27.5%) and suspend (8.7%). They were fulfilled in 80% of the cases. Annual consumption during 2023 was 1273.5 DDD/100 bed-days, representing an increase of 7% compared to 2022 (1183.33).There was a prescription for empirical imipenem to treat respiratory infection, in which de-escalation of treatment was recommended, but it was not accepted. Annual consumption during 2023 was 12.5 DDD/100 bed-days, achieving a decrease of 73% compared to the previous year (46.75). In global terms, the consumption of carbapenems during 2023 was 2170.16 DDD/100 bed-days, achieving a reduction of 4.21% compared to 2022 (2265.63). Conclusion and Relevance Ertapenem is mainly prescribed as a targeted antibiotic whereas meropenem is used empirically. Global consumption of carbapenems has decreased compared to the previous year. The interventions of ASP are essential in the reduction of broad-spectrum antibiotics. References and/or Acknowledgements Conflict of Interest No conflict of interest
Authors: D Tejada Marín, J Preciado Goldaracena, A Magallón Martinez, N Alzueta Isturiz, T Rubio Obanos, S Erdozain Sanclemente
Language: English
Subfield: Applied Microbiology and Biotechnology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4408375727